Immunopharmacological profile and therapeutic perspectives of anti- TNFα-therapies;Immunpharmakologisches profil und therapeutische perspektiven von anti- TNFα-therapien

Zeitschrift fur Rheumatologie

Volumn 57, Issue 5, 1998, Pages 294-297

  Fenner, H ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HYBRID PROTEIN; IMMUNOGLOBULIN G; INTERCELLULAR ADHESION MOLECULE 1; LEUKOTRIENE; NEUTRALIZING ANTIBODY; PROSTANOID; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; CARTILAGE; CELL MIGRATION; CONFERENCE PAPER; DOSE RESPONSE; ENZYME ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; GENE EXPRESSION; IMMUNOCOMPETENT CELL; IMMUNOPHARMACOLOGY; LONG TERM POTENTIATION; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031796791     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003930050114     Document Type: Conference Paper

References (4)

1. Brennan FM, Browne KA, Green PA et al (1997) Reduction in serum matrix metalloproteinases 1 and 3 in rheumatoid arthritis patients following anti-TNFα (cA2) therapy. Br J Rheumatol 36:653-650
2. Feldmann M, Elliott MJ, Woody JN, Maini RN (1997) Anti-tumor necrosis factor α therapy in rheumatoid arthritis. Advances in Immunology, p 283-350
3. Fenner H (1995) Down regulation of TNF-mediated effector mechanisms by anti-TNF therapies. In: Clot J, Sany J (eds) New tools for diagnosis and therapeutics. Monteplier
4. Paleolog EM, Hunt M, Elliott M et al (1996) Monoclonal anti-tumor necrosis factor α deactivates vascular endothelium in rheumatoide arthritis. Arthr Rheum 39:1082-1091